http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011138021-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
| filingDate | 2010-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011138021-A |
| titleOfInvention | Combination of Avermectin or Milbemycin with Adrenergic Receptors for the Treatment or Prevention of Dermatological Diseases |
| abstract | 1. The combination of a compound of the avermectin group or milbemycin group and a compound of the alpha-1- or alpha-2-adrenergic receptor agonist group for its use as a medicine in the treatment and / or prevention of dermatological diseases. The combination according to claim 1 for its use as a medicine in the treatment and / or prevention of rosacea. The combination according to claim 1 for its use as a medicine in the treatment and / or prevention of ocular rosacea. The combination according to claim 1, characterized in that it contains a compound of the avermectin group and a compound of the alpha-2-adrenergic receptor agonist group. A combination according to any one of claims 1 to 4, characterized in that the compound of the avermectin group is selected from ivermectin, invermectin, avermectin, abamectin, doramectin, eprinomectin and selamectin, aversectin B, AB or C, emamectin B1a, emamectin B1b and their derivatives, or latidectin. 6. A composition according to any one of claims 1 to 3, characterized in that the compound of the milbemycin group is selected from lepimectin, milbemectin, milbemycin oxime and moxidectin, 6-ethylleptimectin, 6-methyllepimectin and its derivatives or nemadectin α, β, γ or δ.7. A combination according to any one of claims 1 to 3, characterized in that the compound of the alpha-1-adrenergic receptor agonist group is selected from metaraminol, midodrin, methoxamine, mefentermin, phenylephrine, oxymetazoline, tetrahydrozoline, naphazoline, xylometazoline or their salts. 8. The combination according to any one of claims 1 to 4, characterized in that the alpha-2-adrenergic receptor agonist compound is selected from apraclonidine, brimonidine, clonidine, dexmedetomidine, guanabenza acetate, lidamidi |
| priorityDate | 2009-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 82.